期刊文献+

胆碱能M受体:膀胱过度活动症治疗的关键 被引量:3

The muscarinic receptor:the keypoint of overactive bladder's therapy
下载PDF
导出
摘要 膀胱过度活动症(overactive bladder,OAB)是一种以尿急症状为特征的症候群,常伴有尿频和夜尿症状,可伴或不伴有急迫性尿失禁。存在于膀胱逼尿肌的胆碱能M受体是介导OAB发生的关键。抗胆碱能药物是目前临床治疗OAB最基本的药物,在抑制膀胱逼尿肌不自主收缩、改善OAB症状方面发挥了重要作用。本文从分子结构、受体选择性、药代动力学、临床特点和药物不良反应等方面对目前常用的5种商品化的抗胆碱能药物进行综述。 Overactive bladder(OAB) is defined as a syndrome which represented by the characteristics of urgency,usually with frequency and nocturia,and with or without urge urinary incontinence.The muscarinic receptor,which locates in the detrusor of bladder,has been considered to be a key mediator of OAB.As the first-line medication in the management of OAB,the antimuscarinic agent plays an important role in inhibiting involuntary contraction of detrusor and relieving OAB symptoms.We herein review the molecular structure,receptor selectivity,pharmacokinetics,clinical application and adverse event of the five antimuscarinic agents commercially available in the market.
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2012年第1期99-102,共4页 Fudan University Journal of Medical Sciences
关键词 膀胱过度活动症 M受体 抗胆碱能药物 overactive bladder muscarinic receptor antimuscarinic drug
  • 相关文献

参考文献18

  • 1Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function, report from the standardization sub-committee of the intenational con tinence society[J]. Neurourol Urodyn ,2002,21 (2) : 167.
  • 2Abrams P, Andersson KE. Muscarinic receptor antago nists for overactive bladder[J]. BJ U Int, 2007,1()1) ( 5 ) :987- 1006.
  • 3徐世元.乙酰胆碱受体分子结构的研究进展[J].国外医学(麻醉学与复苏分册),1997,18(4):193-197. 被引量:3
  • 4Matsui M, Motomura D, Karasawa H, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic aeetylcholinc receptor gene for the M3 subtypc[J]. PNAS,2000,97(17):9579 - 9584.
  • 5Matsui M, Motomura D, Fujikawa T, et. al. Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable [J].J Neurosci. 2002,22(24) : 10627-10632.
  • 6Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterod- inea new bladder selective antimuscarinic agent[J]. Eur J Pharmacol,1997,327(2 - 3) :195 - 207.
  • 7Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with Those of subtype selective muscarinic receptor antagonists[J]. Eur J Pharmacol,1998,349(2 - 3) :285 - 292.
  • 8Ikeda K,Kobayashi S,Suzuki M,et al. 3 receptor antago- nism by the novel antimuscarinie agent solifenacin in the urinary bladder ands alivary gland[J]. Naunyn Schmiede berg' s Arch Pharmacol,2002,366(2) :97 - 103.
  • 9Napier CM, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype[J]. Neurourol Urodyn ,2002,21:A445.
  • 10Hegcle SS. Muscarinic receptors in the bladder.from basic research 1o therapeutics[J]. Br J P harmacol , 2006 ,14 7 (S2):S83-S85.

共引文献2

同被引文献77

  • 1徐斌,张维斌,祖金凤.HPLC法测定酒石酸托特罗定中左旋异构体杂质[J].齐鲁药事,2006,25(8):471-472. 被引量:4
  • 2TAKEI M , HOMMA Y,the Japanese Tolterodine Study Group.Long-term safety, tolerability and efficacy of extended-releasetolterodine in the treatment of overactive bladder in Japanese pa-tients[ J]. Int J Urology,2005 ,12(5 ) :456 -464.
  • 3国家食品药品监督管理局.国家药品标准[S].2003年版.39册,2003 :109 -110.
  • 4张小华,李璟,魏顺金,齐广辉.L-酒石酸托特罗定的合成[J].中国新药杂志,2007,16(22):1895-1897. 被引量:4
  • 5Pagoria D, 012onnor RC, Guralnick ML, et al. Antimuscarinicdrugs : review of the cognitive impact when used to treat overactive bladder in elderly patients [ J ]. Curr Urol Rep, 2011, 12 ( 5 ) : 351-357.
  • 6Cardozo L, Hessd? rfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial[J]. BJU Int, 2008, 102(9) : 1120-1127.
  • 7Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats [ J ]. Eur J Pharmacol, 2004, 492(2-3) : 243-250.
  • 8Milsom I, Axelsen S, Kulseng-Hansen S, et al. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries[ J]. Acta Obstet Gyne- col Scand, 2009, 88(6) : 693-699.
  • 9Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenaein suecinate and extend- ed release toherodine at treating overactive bladder syndrome: results of the STAR trial[J]. Eur Urol, 2005, 48(3) : 464-470.
  • 10Karrarn MM, Toglia MR, Serels SR, et al. Treatment with solifena- cin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind,placebo- eontroned trial[J]. Urology, 2009, 73 (1) : 14-18.

引证文献3

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部